Is Dover Corporation (DOV) a risky stock?
As of July 21, 2026, Clavix grades Dover Corporation (DOV) A for risk, a composite score of 82 out of 100 on an A+ to F scale, which puts DOV in the "low risk" band. The grade is a risk read for educational purposes, not a buy or sell recommendation.
Grade as of July 21, 2026. Clavix regrades every trading day.
The five risk dimensions behind DOV's grade
Each Clavix grade is a composite of five independent reads. Higher is safer. Here is how DOV scores on each, as of July 21, 2026.
What's moving DOV's risk right now
Company-specific signals Clavix flags behind DOV's current grade, drawn from recent news and filings as of July 21, 2026.
Analysts say Dover's upcoming earnings report may not beat expectations, which could weigh on the stock if results meet or fall short of forecasts.
Independent Financial Group bought $1.37 million in Dover shares and Regents Gate Capital purchased 40,800 shares, both as new first-quarter stakes. An 8-K filing was also logged; no single catalyst stands out.
Dover's CPC Biotech subsidiary rolled out a new one-inch flow path, single-use sterile disconnect aimed at biopharmaceutical manufacturers. The launch adds to Dover's bioprocessing product line in a growing equipment market.
What a A grade means
On the Clavix A+ to F scale, DOV's composite of 82 falls in the A band (80–100), read as "low risk." The scale is fixed, so the meaning never moves.
This page is generated from Clavix's own risk model and is for educational purposes only. It is not investment advice or a recommendation to buy or sell DOV or any security. Grades are risk indicators, not predictions of return. Data may be delayed.